These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 22153730)
1. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial. Johnsen E; Jørgensen HA; Kroken RA; Løberg EM Eur Psychiatry; 2013 Mar; 28(3):174-84. PubMed ID: 22153730 [TBL] [Abstract][Full Text] [Related]
2. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. Kjelby E; Jørgensen HA; Kroken RA; Løberg EM; Johnsen E BMC Psychiatry; 2011 Aug; 11():145. PubMed ID: 21884578 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. Johnsen E; Kroken RA; Wentzel-Larsen T; Jørgensen HA BMC Psychiatry; 2010 Mar; 10():26. PubMed ID: 20334680 [TBL] [Abstract][Full Text] [Related]
4. Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. Johnsen E; Sinkeviciute I; Løberg EM; Kroken RA; Hugdahl K; Jørgensen HA BMC Psychiatry; 2013 Sep; 13():241. PubMed ID: 24079855 [TBL] [Abstract][Full Text] [Related]
5. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905 [TBL] [Abstract][Full Text] [Related]
6. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. Jing Y; Kim E; You M; Pikalov A; Tran QV J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195 [TBL] [Abstract][Full Text] [Related]
7. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070 [TBL] [Abstract][Full Text] [Related]
8. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
9. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK; Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435 [TBL] [Abstract][Full Text] [Related]
11. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032 [TBL] [Abstract][Full Text] [Related]
12. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905 [TBL] [Abstract][Full Text] [Related]
13. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ; Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Olfson M; Gerhard T; Huang C; Lieberman JA; Bobo WV; Crystal S Schizophr Bull; 2012 Jun; 38(4):845-53. PubMed ID: 21307041 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK; Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434 [TBL] [Abstract][Full Text] [Related]
16. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576 [TBL] [Abstract][Full Text] [Related]
18. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Barbee JG; Conrad EJ; Jamhour NJ J Clin Psychiatry; 2004 Jul; 65(7):975-81. PubMed ID: 15291687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]